Dermatomyositis in rheumatologist's view

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSCHAINBERG, C. G.
dc.contributor.authorADEDUNTAN, R.
dc.date.accessioned2023-02-09T20:00:30Z
dc.date.available2023-02-09T20:00:30Z
dc.date.issued2014
dc.description.abstractDermatomyositis (DM) is a chronic idiopathic inflammatory systemic diseasecharacterized by muscle inflammation due to perivascular involvement, usually expressedby weakness; typical cutaneous inflammation may accompany, precede or follow themuscle complaint. DM can occur at any age. In general it is believed that juveniledermatomyositis (JDM), which occurs before age 18, encompass more vasculopathy andless autoantibodies compared to the disease that affects adults. For adults, the peakincidence is close to 50 years of age, there is a female predominance and it is estimatedthat the incidence of DM is close to 9.5 cases per million people. © 2015 by Nova Science Publishers, Inc. All rights reserved.
dc.identifier.citationSchainberg, C. G.; Adeduntan, R.. Dermatomyositis in rheumatologist's view. In: . DERMATOLOGY RESEARCH ADVANCES: NOVA SCIENCE PUBLISHERS, INC., 2014. p.295
dc.identifier.isbn9781634633444; 9781634633062
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/51181
dc.language.isoeng
dc.publisherNOVA SCIENCE PUBLISHERS, INC.
dc.relation.ispartofDERMATOLOGY RESEARCH ADVANCES
dc.rightsrestrictedAccess
dc.rights.holderCopyright NOVA SCIENCE PUBLISHERS, INC.
dc.titleDermatomyositis in rheumatologist's view
dc.typebookPart
dc.type.categorybook chapter
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryisous
hcfmusp.author.externalADEDUNTAN, R.:Division of Immunology and Rheumatology, Stanford University, School of Medicine, Stanford, United States
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcCLAUDIA GOLDENSTEIN SCHAINBERG
hcfmusp.description.beginpage295
hcfmusp.origemSCOPUS
hcfmusp.origem.scopus2-s2.0-84958854022
hcfmusp.relation.referenceDalakas, M.C., Pathogenesis and therapies of immune-mediated myopathies Autoimmun. Rev., 11, pp. 203-206
hcfmusp.relation.referenceGutierrez, Jr.A., Wetter, D.A., Calcinosis cutis in autoimmune connective tissue diseases (2012) Dermatol. Ther., 25, pp. 195-206
hcfmusp.relation.referenceHak, A.E., de Paepe, B., de Bleecker, J.L., Tak, P.P., de Visser, M., Dermatomyositis and polymyositis: new treatment targets on the horizon (2011) Neth. J. Med., 69, pp. 410-421
hcfmusp.relation.referenceHuber, A.M., Robinson, A.B., Reed, A.M., Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference (2012) Arthritis. Care Res., 64, pp. 546-553. , (Hoboken)
hcfmusp.relation.referenceLam, C., Vleugels, R.A., Management of cutaneous dermatomyositis (2012) Dermatol Ther, 25, pp. 112-134
hcfmusp.relation.referenceMarie, I., Mouthon, L., Therapy of polymyositis and dermatomyositis (2011) Autoimmun. Rev., 11, pp. 6-13
hcfmusp.relation.referenceMarie, I., Morbidity and mortality in adult polymyositis and dermatomyositis (2012) Curr. Rheumatol. Rep., 14, pp. 275-285
hcfmusp.relation.referencePestronk, A., Acquired immune and inflammatory myopathies: pathologic classification (2011) Curr. Opin. Rheumatol., 23, pp. 595-604
hcfmusp.relation.referenceRider, L.G., Werth, V.P., Huber, A.M., (2011) Arthritis. Care Res., 63, pp. 118-157. , Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). (Hoboken)
hcfmusp.relation.referenceWang, D.X., Shu, X.M., Tian, X.L., Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review (2012) Clin. Rheumatol., 31, pp. 801-806
hcfmusp.relation.referenceRosa Neto, N., Goldenstein-Schainberg, C., Juvenile dermatomyositis: review and update of the pathogenesis and treatment (2010) Rev. Bras. Reumatol., 50, pp. 299-312
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication46931d7d-36bf-4de1-a2d5-5a7f2e382503
relation.isAuthorOfPublication.latestForDiscovery46931d7d-36bf-4de1-a2d5-5a7f2e382503
Arquivos
Coleções
Livros e Capítulos de Livros - FM/Outros
Livros e Capítulos de Livros - LIM/17